Pharmaceutical innovations and costs are an important part of any discussion about where our health care system is today and where it is headed
doi: 10.1007/s11756-021-00758-1 144 SinghA.GairolaK.UpadhyayV.KumarJ
1 The risk of CI can be compounded by medications that contribute to either constipation or volume depletion or that are independently associated with CI
Mutations in genes such as -synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), glucocerebrosidase (GBA), and tau protein (MAPT) can also cause hereditary PD or increase PD risk
Consistent with previous observations 13 , we demonstrated that exendin-P5 exhibited faster G s conformational transitions, relative to GLP-1 and exendin-4, and this was coupled with faster dissociation of the G protein heterotrimer in the Nanobit assay (Figure 7B-C)
45 Thus, the substantial costs need to be weighed against the (dollar-denominated) clinical benefits